卡巴他赛与177Lu-PSMA-617两种序贯方案治疗转移性去势抵抗性前列腺癌的比较:一项回顾性多中心研究(LuCaS)
这项回顾性多中心队列研究纳入2015年1月至2023年12月间接受177Lu-PSMA-617与卡巴他赛序贯治疗的68例转移性去势抵抗性前列腺癌患者,比较两种给药顺序对生存结局的影响。主要终点无进展生存期-2(PFS-2)在LU-CA组与CA-LU组分别为10.8个月和11.7个月(p=0.422),中位总生存期分别为16.6个月和19.9个月(p=0.917)。结论认为两种药物的序贯顺序未显著影响生存结局,但需要前瞻性数据来优化序贯策略。
要点
- LU-CA组与CA-LU组的中位PFS-2分别为10.8个月和11.7个月(p=0.422)。
- LU-CA组与CA-LU组的中位OS分别为16.6个月和19.9个月(p=0.917)。
- 177Lu-PSMA-617首选时ORR为23.1%,卡巴他赛后为16.1%;卡巴他赛首选时ORR为25.6%,177Lu-PSMA-617后为31.3%。
核心结论
- 卡巴他赛与177Lu-PSMA-617之间的治疗序贯顺序未显著影响mCRPC患者的生存结局。
- 作者认为两种药物均可有效整合入mCRPC治疗范式,无需担忧序贯顺序的影响。
- 作者指出需要前瞻性数据来优化序贯策略并探索其对特定患者亚组的影响以实现更个性化诊疗。
研究设计与样本
- 回顾性、多中心队列研究,纳入2015年1月至2023年12月间接受177Lu-PSMA-617与卡巴他赛序贯治疗的mCRPC患者68例。
- 主要终点为无进展生存期-2(PFS-2)。
主要发现
- LU-CA组与CA-LU组的中位PFS-2分别为10.8个月和11.7个月(p=0.422)。
- LU-CA组与CA-LU组的中位OS分别为16.6个月和19.9个月(p=0.917)。
- 177Lu-PSMA-617首选时ORR为23.1%,卡巴他赛后为16.1%;卡巴他赛首选时ORR为25.6%,177Lu-PSMA-617后为31.3%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cabazitaxel and 177Lu-PSMA-617 have been shown to improve survival in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and androgen receptor pathway inhibitors (ARPI). we aimed to evaluate the impact of sequencing cabazitaxel and 177Lu-PSMA-617 on survival outcomes in patients with mCRPC. PATIENTS AND METHODS: This is a retrospective, multicenter, cohort study which included patients with mCRPC who received sequential treatment with 177Lu-PSMA-617 and cabazitaxel between January 2015 and December 2023. Primary outcome was progression-free survival-2 (PFS-2) RESULTS: A total of 68 patients with mCRPC who received sequential 177Lu-PSMA-617 and cabazitaxel were included in the study. The primary outcome, progression-free survival-2 (PFS-2), was similar in patients treated with 177Lu-PSMA-617 first (LU-CA) and those receiving cabazitaxel (CA-LU) first (10.8 and 11.7 months, respectively; p = 0.422). The median overall survival (OS) was also similar in the LU-CA and CA-LU groups (16.6 and 19.9 months, respectively; p = 0.917). The objective response rate (ORR) for 177Lu-PSMA-617 was 23.1 % when used first and 16.1 % after cabazitaxel. ORR for cabazitaxel was 25.6 % and 31.3 % when used as the first agent and when used after 177Lu-PSMA-617, respectively. CONCLUSIONS: In conclusion, treatment sequencing between cabazitaxel and 177Lu-PSMA-617 did not significantly affect survival outcomes in patients with mCRPC. These findings suggest that both drugs can be effectively integrated into the mCRPC treatment paradigm without concerns about the effect of sequencing. However, prospective data are needed to optimize sequencing strategies and explore their impact on specific patient subgroups for more personalized care.
引用
- Bolek H, Yazgan SC, Ceylan F, et al. Comparison of two alternative sequences with cabazitaxel and 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: A retrospective multicenter study (LuCaS). Eur J Cancer. 2025. PMID: 39813762. doi:10.1016/j.ejca.2025.115226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。